Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MT-1303 in Moderate to Severe Active Crohn's Disease
2014-002556-77Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing MT-1303 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Sep 2014; status: completed.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-002556-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002556-77.